Abstract
The current report describes the development of a dual modality tomographic agent for both positron emission tomography and magnetic resonance imaging (PET/MRI). The dual-modality agent in this study was based on a 124I (PET) radiolabeled tri-gadolinium endohedral metallofullerene Gd3N@C80 (MRI) nanoprobe platform. The outer surface of the fullerene cage of the Gd3N@C80 metallofullerenes was surface functionalized with carboxyl and hydroxyl groups (f-Gd3N@C80) using previously developed procedures and subsequently iodinated with 124I to produce 124I-f-Gd3N@C80 nanoprobe. Orthotopic tumor-bearing rats were infused intratumorally by convection-enhanced delivery (CED) with the 124I-f-Gd3N@C80 agent and imaged by MRI or micro PET. The anatomical positioning and distribution of the 124I-f-Gd3N@C80 agent were comparable between the MRI and PET scans. The 124I-f-Gd3N@C80 dual-agent distribution and infusion site within the tumor was clearly evident in both T1- and T2-weighted MR images. The results demonstrate the successful preparation of a dual-modality imaging agent, 124I-f-Gd3N@C80, which could ultimately be used for simultaneous PET/MR imaging.
Highlights
The ability to perform comprehensive evaluations of anatomical, functional and molecular imaging data is important for early detection and accurate prognosis of cancer
As simultaneous positron emission tomography (PET)/MR imaging progresses toward full clinical integration and application, the development of imaging agents with dual-modality properties will provide an important component to advancements in research and clinical applications in this area
In a typical iodination reaction involving the radiolabeling of proteins or antibodies, the benzene ring of tyrosine is labeled at the ortho position relative to the hydroxyl group [45]
Summary
The ability to perform comprehensive evaluations of anatomical, functional and molecular imaging data is important for early detection and accurate prognosis of cancer In many cases, this information is acquired using several imaging modalities with various contrast agents being administered during multiple hospital visits. As simultaneous PET/MR imaging progresses toward full clinical integration and application, the development of imaging agents with dual-modality properties will provide an important component to advancements in research and clinical applications in this area. Gd3N@C80(OH)n system in a cell viability study of hen brain and human neuroblastoma SH-SY5Y cells [33] Overall, these reports demonstrated that fullerenes have low systemic toxicity and ameliorate inflammatory responses due to radical and ROS scavenging properties [22,23,24,29,31,32].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
